Replies to post #27784 on CBA Florida Inc. (fka CBAI)

[MrLong]

No Hot Air over Here. Just the Facts.

Active Companies in Tissue Engineering & Cell Therapy Stem cell and other pluripotentent cells, biomaterials and other products providing cell- and tissue-based regeneration and therapy are actively under development by hundreds of companies, according to a new report by MedMarket Diligence, LLC.

Cell Therapy and Tissue Engineering Applications
FOR IMMEDIATE RELEASE

PR Log (Press Release) – Feb 23, 2010 – Stem cell therapy has drawn much attention in recent years, but the controversy has actually overshadowed the tremendous research advances and clinical successes of cell therapy of many types (beyond embryonic) as well as a wide range of technologies that accomplish "tissue engineering" in which tissues are reconstructed, repaired or even replaced in order to address disorders and traumas.

The applications are as wide ranging as there are medical specialties. Technologies, products and commercial developments are being pursued in cardiovascular and vascular, neurological, orthopedic, urological, skin/integumentary, dental, organ transplantation and preservation, ophthalmology, general, gastrointestinal, gynecologic and other, cancer, cord blood and cell banking. MedMarket Diligence has published its 2010 report on "Tissue Engineering, Cell Therapy and Transplantation, 2009-2018", detailed at http://www.mediligence.com/rpt/rpt-s520.htm.

As illustrated in the accompanying diagram, the specific applications are many.

At a minimum, 150 companies are active developing these applications, and have already driven the formation of a $6.9 billion market. The active companies include the following:

3DM Inc., Aastrom Bioscience Inc., Acorda Therapeutics Inc., Advanced BioHealing, Inc., Advanced Cell Technology, Inc., Advanced Medical Solutions PLC, Aeolus Pharmaceuticals, Aldagen, Inc., Alexion Pharmaceuticals, Angioblast Systems, Inc., Angiotech Pharmaceuticals, Inc., Ariad Pharmaceuticals Inc., Arteriocyte Medical Systems, Inc., Athersys, Inc., Avax Technologies Inc., Avita Medical Limited, Baxter International Inc., BeFutur Biotechnologies, Bio Nova International, Biocomposites, Biocoral Inc., Bioheart Inc., BioHybrid Technologies, BioLife Solutions Inc., Biomet, Inc., BioMimetic Therapeutics, BioSante Pharmaceuticals, Inc., BioSyntech, BioTissue Technologies GmbH, Boston Scientific Corporation, BrainStorm Cell Therapeutics, Inc., Breonics Perfusion Technologies, Inc., BTG International Ltd., California Stem Cells Inc., Capstone Therapeutics, Celgene Corporation, CellECT Bio Inc., Cellerix SA, CellSeed, Inc., CellTran Ltd., Cellular Dynamics International, Centocor Ortho Biotech, Inc., Cerco Medical, co.don AG, ConMed Linvatec, Cook Group, CorCell Companies, Inc., Cryo-Cell International, Inc., CryoLife, Inc., Curis Inc., Cyclacel Pharmaceuticals, Inc., Cytograft Tissue Engineering, Cytomatrix LLC, Cytori Therapeutics Inc., ES Cell International, Exactech, Inc., Excorp Medical, Inc., FibroGen, Inc., Fidia Advanced Biopolymers/Anika Therapeutics, Inc., Forticell Bioscience, Inc., Gamida Cell Ltd., Garnet BioTherapeutics, Genta, Inc., GenVec, Inc., Genzyme Corporation, Geron Corporation, Glycotex, Inc., HepaLife Technologies, Inc., Hospira, Humacyte, Inc., InCytu Inc., Inion Ltd., Innogenetics, InnovaCell Biotechnologie GmbH, Integra LifeSciences Inc., ISTO Technologies Inc., Johnson & Johnson Inc. (Ethicon Biosurgery, DePuy), Kensey Nash, Kerecis EHF, LifeCell Inc., LifeStem Inc. (Calba Tech, Inc.), Living Cell Technologies Ltd., Lonza Group Ltd., MaxCyte, Medtronic, Mesoblast Limited, MG Biotherapeutics, LLC, MicroIslet Inc., Miltenyi Biotec, Musculoskeletal Transplant Foundation, Natural Implant, NellOne Therapeutics, Inc., NeoStem, Inc., Neuralstem, Inc., cNeuroGeneration, Inc., NeuroNova AB, Neurotech, Novartis International AG, Novo Nordisk A/B, Novocell Inc., OncoMed Pharmaceuticals, Organogenesis Inc., Organovo, Inc., Orthovita, OSI Pharmaceuticals, Osiris Therapeutics Inc., Osteotech, Inc., Pioneer Surgical Technologies, Pluristem Therapeutics Inc., Poly-Med, Inc., Polyganics BV, ProChon Biotech, Ltd., Progenitor Cell Therapy Inc., ProNeuron Biotechnologies, Inc., Protein Polymer Technologies Inc., ReGen Biologics Inc., Reinnervate Ltd., ReNeuron Ltd., Revivicor, Inc., RTI Biologics, Inc., Sanofi-Aventis, Sciperio Inc., Serica Technologies, Inc./Allergan, Sernova Corp., Smith & Nephew Ltd., SpineSmith Partners, LP, Stem Cell Pharma Inc., Stem Cell Sciences UK Ltd., Stem Cell Therapy International, Inc./Histostem Co. Ltd., StemCell Technologies Inc., StemCells Inc., Stryker Corporation, Synovis Life Technologies, Inc., Targeted Genetics Corporation, TEI Biosciences Inc., Tengion, Inc ., Tepha Inc., Theracell, Inc., ThermoGenesis Corp., TiGenix N.V., Transition Therapeutics Inc., TriStem Corporation, Vesta Therapeutics, ViaCell/PerkinElmer, Vital Therapies, Inc., Vitrolife AB, and Zimmer, Inc.

Many hurdles remain to achieve an even partial level of the success frequently promised by advocates of cell therapy and tissue engineering, but the existing market is viable and growing dramatically.